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ABSTRACT 
Extracellular vesicles released into urine (uEVs) can represent interesting biomarkers of renal cell 
damage. CD133, a stem/progenitor cell marker expressed by renal progenitor cells, is highly 
expressed in the uEVs of healthy subjects. We here evaluated the level of CD133 in the uEVs of 
patients with acute and chronic glomerular damage by cytofluorimetric analysis. The level of 
CD133+ uEVs was significantly decreased in paediatric acute glomerulonephritis patients during the 
acute phase of renal damage, while it was restored after the subsequent recovery. A similar decrease 
was also observed in chronic glomerulonephritis patients. Moreover, CD133+ uEVs significantly 
declined in type 2 diabetic patients, used as validation group, with lowest levels in albuminuric 
patients with diabetic nephropathy. Indeed, ROC curve analysis indicates the ability of CD133+ 
uEV values to discriminate the health condition from that of glomerular disease. In parallel, a 
significant decrease of CD133 in renal progenitor cells and in their derived EVs was observed in 
vitro after cell treatment with a combination of glucose and albumin overload, mimicking the 
diabetic condition. These data indicate that the level of CD133+ uEVs may represent an easily 
accessible marker of renal normal physiology and could provide information on the “reservoire” of 
regenerating cells within tubules. 
	 	
 3 
INTRODUCTION 
The assessment and diagnosis of renal function during acute and chronic pathologies affecting the 
renal compartments is, at present, mainly based on the levels of retention markers such as creatinine 
and urea. In addition, alternative blood and urinary biomarkers appear to be precious tools which 
can refer not only to the degree of renal damage but also to the pathophysiological state of the 
kidney. In particular, urine detection markers already used in the clinical practice (13), such as 
NGAL and Cystatin C, appear as the most promising ones as they directly derive from the renal 
compartment and from cells of the urinary tract. In addition, urine is a ready available sample easy 
to collect without the need of any invasive procedure.  
Extracellular vesicles (EVs) are round vesicles released in biological fluids by almost all types of 
cells, and they contain proteins and other molecules directly correlated with the tissue from which 
they originate. Particularly, urinary EVs (uEVs) carry molecules that are characteristic of the 
epithelial cells present in the whole length of the urinary tract (23, 25). Accordingly, uEVs are 
attracting increasing interest as potential urinary biomarkers, since they may be a precious source of 
information related to the pathophysiological state of renal tissue. Indeed, data have been so far 
provided on the role of uEVs as biomarkers of glomerular diseases, including diabetes, tubular 
damage and renal fibrosis (4, 22, 27, 28).  
CD133 molecule represents a marker of a population of tubular cells, intercalated between the other 
epithelial cells, with the ability to survive after damage and proliferate in response to cell injury, 
suggesting a role of this protein as marker of renal regenerative capability (3). CD133 itself may 
play a role in the increased proliferation of regenerating clonal tubular cells in acutely damaged 
kidney through the permissive effect on the activation of the Wnt/β-Catenin pathway (2). 
Interestingly, we previously reported that CD133, which is expressed at high level by the uEVs of 
healthy subjects, was reduced in the uEVs of transplanted patients with acute tubular necrosis 
occurring after a renal transplantation and increased in the first week following transplant (7). These 
results suggest that the level of CD133+ uEVs can mirror the regenerative state of the renal tubular 
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compartment in healthy and in pathological conditions. However, no data are currently available on 
CD133+ uEV level in patients with acute and chronic glomerular damage. 
It is well established that glomerular damage affects the functionality of the tubular compartment, 
being proteinuria a main prognostic factor for interstitial fibrosis (11, 12). Indeed, tubular atrophy 
together with proteinuria represent the most reliable predictors of renal function in glomerular 
diseases (18, 30, 31). 
Therefore, the aim of the present study was to verify if variation of CD133+ uEVs level, previously 
observed in a group of acutely tubular damaged patients (7), also occurs in acute and/or persistent 
diseases involving the glomerular compartment. In this study, changes in CD133+ uEVs level 
during time were assessed in paediatric patients with acute post-streptococcal glomerulonephritis, 
characterized by alteration of the glomerular filtration barrier, proteinuria and resolution by minimal 
medical approaches. In addition, two groups of chronic glomerular diseases were studied. The first 
group included patients with chronic glomerulonephritis (CGN) and proteinuria in the absence of 
renal function impairment, the second one included type 2 diabetic (T2DM) patients with different 
degrees of renal impairment as validation group. 
In both acute and chronic glomerular diseases, the potential role of CD133 as urinary biomarker 
modulated during renal damage was investigated. Finally, in vitro studies were performed to 
evaluate whether CD133+ EVs could be released by renal CD133+ expressing cells. To this end, 
CD133+ EV release was evaluated in cells exposed to hyperglycaemia and albumin overload. 
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METHODS 
 
Study Groups 
All patients enrolled in the present study provided informed written consent for the study. The study 
protocol was approved by the Bioethics Committee of the A.O.U. Città della Salute e della Scienza 
Hospital (Protocol number: 0021671). The study was conducted according to the principles 
expressed by the Declaration of Helsinki of 1975, as revised in 2013. The study group was 
composed by a total of 30 paediatric patients and 7 paediatric healthy control subjects. Urine was 
collected from 18 paediatric poststreptococcal GN patients (Table I) at diagnosis and before 
treatment. At time of resampling (1 year), patients were all treatment-free and experienced no 
relapse of proteinuria and/or haematuria after first remission. Samples were also collected from 12 
CGN paediatric patients (Table I) with an active proteinuria and/or haematuria for at least 12 
months. All patients were under minimum steroid treatment at the time of sample recovery without 
additive immunosuppressive drugs.  
The validation group was composed by 47 adult type 2 diabetic patients admitted to the Clinic 
(HbA1c > 48 mmol/mol) and 13 adult healthy subjects age and sex matched. Table II shows patient 
and control clinical data. 
 
Urine collection and EV isolation 
Morning urine samples (around 100 ml) were collected in sterile containers. In parallel biochemical 
analysis were performed by the clinical laboratory of the A.O.U. Città della Salute e della Scienza 
Hospital. Urine samples were centrifuged at 3000 rpm for 15 min to remove whole cells, large 
membrane fragments and other debris. Protease Inhibitor (PI) Cocktail (Sigma-Aldrich, Missouri, 
USA; 100µl PI / 100ml urine) and NaN3 10 mM (Sigma-Aldrich) were added immediately to the 
remaining supernatant. After filtration through 0.8 µm and 0.45 µm filters (Merck Millipore, 
Burlinghton, MA, USA), uEVs were collected from the samples through ultracentrifugation 
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(Beckman Coulter, OPTIMA™ L-100 K Ultracentrifuge, Rotor Type 70-Ti Brea, California, USA) 
at 100,000g for 1 hour at 4°C. The pellet was then resuspended in RPMI (Euroclone, Turin, Italy) + 
1% DMSO (Sigma-Aldrich) and stored at -80°C until use. 
 
EV quantification 
EVs were quantified by nanoparticle tracking analysis (NTA), using the NanoSight NS300 system 
(NanoSight Ltd, Salisbury, UK), configured with a Blue 488 nm laser and a high sensitivity digital 
camera system OrcaFlash 2.8, Hamamatsu C1 1440 (NanoSight Ltd). Briefly, EVs stored in -80°C 
were thawed, strongly vortexed and properly diluted in physiologic solution (Fresenius Kabi Bad 
Homburg, Germany) previously filtered with 0.1 µm filter (Merck Millipore). For each sample, 
three videos of 30-second duration were recorded. The settings of acquisition and analysis were 
optimized and kept constant between (19).  
 
Transmission Electron Microscopy 
Transmission electron microscopy was performed using a Jeol JEM 1010 electron microscope (Jeol, 
Tokyo, Japan) on uEVs coated on 200 mesh nickel formvar carbon-coated grids (Electron 
Microscopy Science, Hatfield, PA, USA). EVs were placed in adhesion for 20 min on the grids that 
were then incubated with 2.5 % glutaraldehyde containing 2 % sucrose. After washings in distilled 
water, EVs were negatively stained with NanoVan (Nanoprobes, Yaphank, NK, USA) and 
analysed. 
 
Cytofluorimetric analysis 
EVs were bound to surfactant-free white aldehyde/sulfate latex beads 4% w/v, 4 µm diameter 
(Molecular Probes, Thermo Fisher, Waltham, MA, USA) for the subsequent cytofluorimetric 
analysis. Thirty µg of EVs were incubated with five µl of beads for 30 minutes at room temperature 
and subsequently for 30 minutes at +4°C. Adsorbed EVs were placed in different vials and 
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incubated with the antibodies reported in Supplementary Table I, with a final dilution of 1:50, for 
15 minutes at +4°C. The adsorbed EVs were then washed and analyzed with a FACSCalibur and 
CellQuest software (Becton Dickinson Bioscience Pharmingen, Franklyn Lake, NJ, USA) 
(Supplementary Table I). The anti-Aquaporin-1 antibody (AQP1) (Santa Cruz Biotechnology, 
Dallas, Texas, USA) was conjugated to an Alexa Fluor® 488 dye through the Alexa Fuor® 
Antibody Labeling Kit (Molecular Probes) following the manufacturer’s instructions. During the 
cytofluorimetric acquisition the gating strategy was set on the physical parameters dot plot. Controls 
corresponded to EVs adsorbed on beads and marked with FITC-, PE- or APC- conjugated Mouse 
IgG1 Isotypes (all purchased by Miltenyi, Bergisch Gladbach, Germany). 
 
uEVs floating purification 
To avoid protein contamination and to increase the purity of uEVs, a floating protocol through a 
sucrose gradient was applied as previously described (5, 16). Briefly, uEVs were washed with an 
ultracentrifuge and resuspended in 1.35 ml of buffer (0.25 M sucrose, 10 mM Tris pH 8 and 1 mM 
EDTA, all products purchased by Sigma-Aldrich), transferred to a SW55Ti rotor tube (Beckman 
Coulter) and mixed with 60% stock solution of Optiprep (Sigma-Aldrich) 1:1 ratio. Next, 1.2 ml 
Optiprep 20% solution was layered on top, followed by 1.1 ml of Optiprep 10% solution. The tubes 
were then ultracentrifuged at 350,000 g for 1 hour at +4°C with “no brake” deceleration. The next 
day, five fractions of 1 ml each were collected from the top of the tubes, and each fraction was 
diluted in 25 ml PBS (Lonza, Basel, Switzerland) and washed with an ultracentrifugation at 100,000 
g for 2 hours at +4°C to pellet the EVs. The highest fraction, containing pure EVs, as assessed by 
NanoSight analysis, was then resuspended in 200 µl of serum free DMEM (Lonza) with 1% P/S and 
1% DMSO (both products purchased by Sigma-Aldrich) to allow freezing storage in -80°C until 
use. 
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Cell culture 
CD133+ Renal Progenitor Cells (RPCs) were obtained from biopsies of normal tissue of a human 
surgically removed kidney for polar carcinoma performed (after the approval of ethical committee 
for the use of human tissue of Molinette Hospital; n. 168/2004), as previously described (2). In 
particular, the outer medullary tissue at the opposite pole of the tumor was used. The absence of 
tumor infiltrating cells was evaluated by pathologists. Tissue samples were cut to obtain 3–5 mm3 
fragments, digested in 0.1% collagenase type I (Sigma-Aldrich) for 30 min at 37°C and 
subsequently forced through a graded series of meshes for the separation of cell components from 
stroma and aggregates. The filtrate was then pelleted by centrifugation. To recover CD133+ cells, 
the single cell suspension underwent magnetic separation for CD133/1 antigen (Miltenyi). CD133+ 
cells (>98% as evaluated by cytofluorimetric analysis) were resuspended in expansion medium 
(Endothelial Cell Growth Basal Medium plus supplement kit, Lonza) and plated at density 1x104 
viable cells/cm2.  
From passages 2 to 4 cells were 48 hours treated with Human Serum Albumin (HSA) (Kedrion, 
Wilmington, DE, USA) at different concentrations (0.1, 1 and 10 mg/ml), Glucose (Sigma Aldrich) 
at different concentrations (5.5 and 27.5 mM) or a combination of HSA 10 mg/ml plus Glucose 
27.5 mM. After 48 hours of treatment and overnight cell starvation, EVs were recovered by 
ultracentrifugation (2 hours, 100,000 g at +4°C). 
 
Western Blot  
Proteins from cells were extracted using RIPA buffer, containing 1% of Phosphatase Inhibitor 
Cocktails, 1% Protease Inhibitors and 1% PMSF (all purchased by Sigma-Aldrich), while proteins 
from EVs were obtained using the same lysis buffer on the ultracentrifuge pellet. Total protein 
concentration was estimated by Bradford (Bio-Rad, Hercules, CA) quantification. Ten µg of EV-
lysates and 50 µg of cells lysates were loaded on Mini-PROTEAN TGX pre-cast electrophoresis 
gels (Bio-Rad). Proteins were subsequently transferred on iBlot nitrocellulose membranes 
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(Invitrogen, Carlsbad, California, US) and blotted with antibodies against CD133 (Miltenyi), Actin 
(Santa Cruz), HSP70/HSC70 (Santa Cruz), Rab5 (Santa Cruz) as reported in Supplementary Table 
I. Chemiluminescent signal was detected using the ECL substrate (Bio-Rad).  
 
Statistical analysis 
The expression of different patient data followed a non-normal distribution, as assessed by 
Kolmogorov-Smirnov test, therefore non parametric tests, such as Mann-Whitney or Kruskal-
Wallis, were performed. Western blot experiments were analysed with student’s t-test and with 
ordinary one-way ANOVA with Dunnett’s multicomparison test. A p-value < 0.05 was considered 
significant.  
Sensitivity and specificity of CD133 as marker of renal damage, and 95% confidence intervals 
(95% CI) were calculated using receiver operating characteristic (ROC) curves. The accuracy of the 
test among different groups of patients was done evaluating areas under curve (AUC) and p-values. 
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RESULTS 
 
Characterization of uEVs from healthy paediatric subjects 
EVs were isolated from urine obtained from paediatric healthy subjects using a protocol based on 
filtration and sequential centrifugations. Transmission electron microscopy (TEM) images showed a 
heterogeneous population of rounded in shape vesicles (Fig. 1A). uEV were also analysed for 
number and size by Nanosight (mean diameter 265.1±69nm) (Fig. 1B).  
Cytofluorimetric analysis was performed using uEV adsorption on latex beads, as this method 
allows the analysis of small vesicles that cannot be analysed using direct cytofluorimetric analysis. 
The gating strategy of the evaluated beads and the setting of the negative threshold is shown in Fig 
1C. The results showed that uEVs from paediatric healthy subjects, as those obtained from adult 
healthy subjects (7), were positive for CD24 and AQ1 renal markers, for the exosomal marker 
CD81 and for the progenitor/stem cell marker CD133. Urinary EVs did not express the vascular 
marker VEGF receptor 2 or the podocyte marker podocalyxin (PDX) (Supplementary Fig. 1A). As 
negative control, beads were incubated with antibodies in the absence of EVs and they did not show 
positive fluorescence (Supplementary Fig. 1B). 
 
Characterization of uEVs from paediatric patients with acute and chronic GN 
uEVs from four different groups of patients suffering of glomerulonephritis were compared: healthy 
subjects, chronic glomerulonephritis (CGN), acute post-infective glomerulonephritis (AGN), either 
at diagnosis (AGN T1) and on day 365, corresponding to the recovery phase (AGN T365). The 
Nanosight analysis showed no significant differences in the mean and mode size of the uEVs 
among the four groups (Fig. 2, A-B). At variance, EV count revealed that the amount of uEVs per 
ml of urine was significantly decreased in CGN patients compared to healthy subjects (Fig. 2C). 
Cytofluorimetric analysis was performed to evaluate the relative amount of CD133 and CD81 
positive uEVs, testing the same quantity of EVs previously shown to saturate the latex beads 
 11 
surface (7). Indeed, as shown in Figure 3, the exosomal marker CD81 did not significantly vary 
among different groups, indicating an equal EVs loading. At variance, we observed a significant 
decrease of CD133 in uEVs of CGN patients compared to healthy subjects. Moreover, CD133+ 
uEVs were also significantly decreased in AGN patients during the acute phase of the disease, to 
return to basal level on day 365. All these results are reported in dot plots graphs (Fig. 3A) and in 
the relative box plots (Fig. 3, C-D). These data indicate that CD133+ uEVs, which mainly derived 
from renal tubular cells (23), are decreased after glomerular damage in both acute and chronic 
conditions.  
Moreover, receiver operating characteristic (ROC) curves were performed, using the values 
determined by the cytofluorimetric analysis, to investigate the potential utility of CD133 as 
predictive biomarker of renal damage. By comparing healthy subjects to acute glomerulonephritis 
patients at day1 (AGN T1) the area under the curve (AUC) value for CD133 was 0.878, with an OR 
(CI 95%) of 19.5 (3-126.5) and p = 0.001 (Fig. 3D). In the context of this analysis the percentage of 
CD133+ uEVs considered as threshold able to discriminate healthy subjects and acutely damaged 
glomerulonephritis patients resulted 36. 
 
Characterization of uEVs from diabetic patients 
We subsequently aimed to validate the reduction of CD133+ uEVs observed after glomerular 
damage in paediatric patients, in patients affected by T2DM-associated glomerular disease. Based 
on the degree of their renal impairment, patients were divided in three groups: normoalbuminuric 
diabetic patients (NAlb DN), microalbuminuric diabetic patients (MiAlb DN) and 
macroalbuminuric diabetic patients (MaAlb DN), and were compared to age and sex matched 
healthy subjects. Nanosight analysis showed that the mean and mode uEV dimension are similar 
among groups. Similarly, no differences in the number of uEVs /ml of urine were detected (Fig. 2, 
D-F).  
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The presence of CD133+ uEVs in T2DM patients was subsequently compared to that of healthy 
subjects by cytofluorimetric analysis. In Figure 4B-C the level of CD81 did not change between 
healthy and diabetic patients, while CD133+ uEVs was significantly decreased in DN patients. 
Moreover, when the analysis of CD133+ uEVs was based on their level of albuminuria, a further 
decrease of CD133+ uEVs was detected in macroalbuminuric patients (Fig. 4D). 
In order to evaluate whether proteins in the urine of albuminuric T2DM patients could affect the 
results of the cytofluorimetric analysis, three uEV pools belonging to the three different T2DM 
groups were purified from contaminating proteins by applying a glucose gradient floating protocol 
(5, 16). Floated uEVs were analysed and compared to a pool of healthy uEVs subjected to the same 
protocol. As reported in Figure 4E the loading of 10 micrograms of proteins from each sample 
showed a significant decrease in CD133 in all T2DM patients, confirming the results of the 
cytofluorimetric analysis. 
ROC curves were also performed on the results obtained from the cytofluorimetric analysis, in 
order to confirm CD133 as a potential predictive biomarker of renal damage. By comparing healthy 
subjects to all T2DM patients the AUC value for CD133 was 0.775, with an OR (CI 95%) of 9.8 
(2.2-42.7) and p = 0.001 (Fig. 3D). In the context of this analysis the percentage of CD133+ uEVs 
considered as threshold able to discriminate healthy subjects and diabetic patients resulted to be 37. 
 
Modulation of CD133+ EV release by CD133+ cells subjected to Albumin and Glucose 
overload 
To evaluate the contribution of renal progenitor cells in the release of CD133+ uEVs , CD133+ renal 
cells were treated with different concentrations of albumin and glucose for 48h (Fig. 5A). As shown 
in Fig 5B, albumin (0.1-10 mg/ml) but not glucose (5.5-27.5 mM) treatment induced a dose 
dependent loss of CD133 expression by CD133+ cells (Fig. 5B). Likewise, albumin load induced 
the loss of CD133+ in CD133+ renal cell derived EVs (Fig. 5C). To mimic diabetes in vitro, CD133+ 
cells were treated with high albumin concentration (10 mg/ml) together with high glucose 
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concentration (27.5 mM), for 48 hours. Western blot revealed a strong decrease in CD133 
expression both in progenitor renal cells and their derived EVs (Fig. 5, D-E). These data support the 
results obtained by analysing patients’ urine, and indicate that proteinuria and glucose may modify 
tubular progenitors cells and promote CD133 loss in cells and in their derived uEVs . 
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DISCUSSION 
 
EVs are constantly released by virtually all cells and their characteristics reflect the state of the cell 
of origin, so that they can mirror tissue health and/or disease. In the present study, we show that the 
levels of CD133+ uEVs, differently from normal subjects, declined in the urine of paediatric and 
adult patients with glomerular disease, suggesting that CD133+ uEVs may represent a marker of 
renal normal physiology. Indeed, ROC curve analysis indicates the ability of CD133+ uEV values to 
discriminate the health condition from that of glomerular disease. 
Since uEVs released by renal tissue could be detected in human urine, EVs may be exploited as 
markers for the physiological/pathological state of the renal tissue. Indeed, proteomic analysis of 
uEVs from healthy subject demonstrated the presence of renal proteins, such as uromodulin, 
aquaporin 1 and aquaporin 2, indicating that the majority of EVs derived from tubular segments (9). 
During glomerular damage, podocyte-released EVs may be detected within urine, (17) and 
podocyte-derived proteins within urinary exosomes were reported as specific markers of glomerular 
injury and chronic renal damage. In particular, exosomal WT1 was described as a marker of focal 
segmental glomerulosclerosis in murine and human studies (29) while CD2AP mRNA was reported 
as a marker of chronic kidney disease (20). The nature of urine vesicles is heterogeneous in type 
and dimension, including larger vesicles, so called microparticles. Indeed, the number of podocyte-
derived microparticles by itself was increased in type 1 diabetic patients, and could predict early 
renal damage (21). 
Besides being considered as biomarkers, EVs may also play a role in the cell-to-cell communication 
along the urinary lumen. Indeed, proximal tubule derived EVs were shown to be internalized by 
distal tubular cells (8). Furthermore, the increase of water flow in recipient cells proved the 
functional transfer of AQP2 from EVs deriving from collecting ducts (26). During glomerular 
disease such as diabetes, podocyte-derived EVs may promote fibrosis of tubular cells, via 
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detrimental glomerular-tubular signals (24). These data suggest that uEVs may orchestrate the 
trafficking of different renal messages occurring during physiological or pathologic conditions. 
In the present study we focused on CD133, a tubular EV marker, previously shown to be highly 
abundant in normal urine (7). Indeed, CD133+ uEV sorting clearly showed the co-expression of 
proximal tubular markers (mainly Aminopeptidase and Aquaporin 1) indicating its origin from cells 
of the proximal tubules (7). Moreover, we herein confirmed that CD133+ EVs are released, at least 
in vitro, by renal CD133+ cells. Similarly CD133+ EVs have been detected in the spinocerebral 
fluids in association with pathological conditions (14, 15) and in cultures of CD133+ 
stem/progenitor cells of nervous and hematopoietic origins (1, 6). Therefore, it could be speculated 
that levels of urinary CD133+ EVs may reflect the number of CD133+ cells lining the lumen of 
renal tubules. 
Interestingly, in paediatric patients with acute post-infective glomerulonephritis, CD133+ uEVs 
were downregulated during the acute phase to return to basal level after 1 year, as the result of 
tissue repair. Similarly, CD133+ uEV level was significantly low in paediatric patients with chronic 
renal disease. This observation suggests that CD133 could be considered a general marker of renal 
tissue damage that may reflect the state of the functional tubular compartment. This is consistent 
with data previously demonstrated in transplanted patients with slow graft function (7). Our results 
were further validated in diabetic patients. Indeed, we found that the reduction of CD133 levels in 
diabetic patients was even more evident in the subgroup of macro-albuminuric patients. 
These data suggest that reduction of CD133+ uEVs in patients with acute and chronic glomerular 
damage reflects the tubular damage occurring in the tubular compartment as a consequence of 
glomerular injury and protein overload. Consistently, in vitro experiments showed that the albumin 
overload decreased the expression of CD133 in cultured cells as well as in their derived EVs. 
Indeed, it is well established that proteinuria may accelerate kidney disease progression (10).  
The analysis of ROC curves confirmed the ability of CD133+ uEV levels to discriminate between 
healthy subjects and patients with renal disease. Moreover, the restoration of CD133+ uEV levels in 
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patients one year after recovery from glomerular damage further supports the correlation of this 
marker with the renal pathophysiological condition. Considering the role of CD133 cells in renal 
repair and regeneration, it can be also inferred, that CD133+ uEVs may represent an easily 
accessible marker of renal regeneration and of the “reservoire” of regenerating cells within tubules.  
In conclusion, it can be speculated that the assessment of CD133+ uEVs level in urine might 
provide a number of benefits. The use of a surface marker may allow a direct and quick evaluation 
compared to intra-vesicle protein, mRNA or microRNAs evaluation. Moreover, this assessment, 
being a percentage of total events, is independent from the number of total EVs in urine and from 
their concentration. Finally, the high level of CD133+ uEVs in normal subjects guarantees a very 
good discrimination between healthy and patients. This marker may therefore provide information 
on the renal parenchyma status and chances associated with tissue recovery after injury without 
invasive procedures, which represents an important step toward biopsy overcoming and patient’s 
safety. The limit of our study relies on the use of a semi-quantitative cytofluorimetric analysis. In 
fact, the absorption onto latex beads was an instrumental requirement for the assessment of small 
EVs. However, it should be considered that several new cytofluorimetric techniques, which are 
currently under evaluation, would allow a direct assessment of the small EV population. This 
implies that future studies may benefit of an easier and direct measurement of uEV number and 
markers. 
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FIGURE LEGENDS 
 
Figure 1. Characterization of uEVs in healthy subjects. (A) Representative Transmission 
Electron Microscopy (TEM) image of uEVs isolated from healthy subjects (scale bar 150nm), and 
an enlargement on one single uEV (scale bar 20nm). (B) Nanoparticle Tracking Analysis (NTA) of 
a representative pool of uEVs showing their size distribution profile. Cytofluorimetric analysis of 
surface markers expressed by healthy subjects uEVs were represented as (C) dot plot (the gating 
strategy and the negative fluorescence controls are reported) and (D) histograms with isotype 
control (black line) plotted on the marker signal (red line). Ten different preparations were tested 
with similar results. 
 
Figure 2. Characterization of uEVs recovered from patients with Acute and Chronic 
glomerular damage. (A, B) Representative Nanoparticle Tracking Analysis (NTA) of uEVs from 
each group of paediatric patients and box plot representation of Mean and Mode values of EVs size 
(nm). (C) Evaluation of EVs concentration in urine of the different groups of paediatric patients. (D, 
E) Representative Nanoparticle Tracking Analysis (NTA) of uEVs from each group of T2DM 
patients and box plot representation of Mean and Mode values of EVs size (nm). (F) Evaluation of 
EVs concentration in the urine of the different groups of T2DM patients. Data are expressed as 
mean ± SE. (*) p<0.05 with unpaired t-test. 
 
Figure 3. Characterization of uEVs obtained from acute damaged patients. (A) Dot plot 
cytofluorimetric analysis of surface markers in uEVs derived from healthy subjects and paediatric 
patients. The gating strategy and the negative fluorescence controls are also reported. Box plot 
representation of cytofluorimetric values of CD81 (grey plot) and CD133 (red plot) percentage (B) 
comparison between healthy subjects (h) and chronic glomerulonephritic patients (CGN), or (C) 
between healthy subjects (h) and acute glomerulonephritic patients (AGN) at day 1 (T1) and year 1 
 24 
(T365) after the damage. (D) ROC analysis for the detection of renal damage in different groups of 
acutely damaged patients using CD133. A table with the CD133 threshold value, the AUC value, 
the p-value and the odd ratios with confidence interval is also reported. 
 
Figure 4. Characterization of uEVs recovered from patients with chronic damage. (A) 
Representative Nanoparticle Tracking Analysis (NTA) of uEVs recovered from healthy subjects (h) 
and diabetic patients (DN). Cytofluorimetric results are reported as dot plot (C) and box plot (B) of 
CD81 (grey plot) and CD133 (red plot) in healthy (h) and diabetic patients (DN). (D) 
Cytofluorimetric evaluation of CD133 in uEVs from healthy (h), diabetic normoalbuminuric 
(NAlb), diabetic microalbuminuric (MiAlb) and diabetic macroalbuminuric (MaAlb) patients. 
(****) p<0.0001, with Kruskal-Wallis multiple comparison test. (E) Western blot analysis of 
CD133 in floating purified uEVs. (F) ROC analysis for the detection of renal damage in different 
groups of diabetic patients using CD133. A table with the CD133 threshold value, the AUC value, 
the p-value and the odd ratios with confidence interval is also reported. 
 
Figure 5. Decrease of CD133 upon HSA and Glucose treatment. (A) Timetable of the 
experiment performed on CD133+ renal cells. (B and D) CD133 levels in CD133+ cells upon 
treatment with increasing concentration of human serum albumin (HSA) (0.1 – 1 – 10 mg/ml) or 
Glucose (5.5 – 27.5 mM) (B) or upon HSA 10 mg/ml and Glucose 27.5 mM combo treatment (D). 
(C and E) CD133 levels in CD133+ cells derived EVs upon HSA treatment (10 mg/ml) (C) or upon 
HSA 10 mg/ml and Glucose 27.5 mM combo treatment. Data are expressed as mean ± SE. (*) 
p<0.05, with unpaired t-test. 
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